Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2CNS 2Sarcoma 1Head & Neck 1Gynecologic 1Genitourinary 1Endocrine 1Dermatologic 1

Conditions

Brain Neoplasms 33Glioblastoma 32Melanoma 21Glioma 19Neuroblastoma 7Carcinoma, Renal Cell 6Carcinoma, Non-Small-Cell Lung 6Astrocytoma 6Ependymoma 5Colorectal Neoplasms 5Central Nervous System Neoplasms 5Recurrence 4Ovarian Neoplasms 4Medulloblastoma 4Lymphoma 4Carcinoma, Hepatocellular 4Thyroid Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Rhabdomyosarcoma 3Pancreatic Neoplasms 3Osteosarcoma 3Meningioma 3Lung Neoplasms 3Gliosarcoma 3Cholangiocarcinoma 3Carcinoma, Transitional Cell 3Vulvar Neoplasms 2Uterine Cervical Neoplasms 2Stomach Neoplasms 2Small Cell Lung Carcinoma 2

Interventions

Nivolumab 2Cisplatin 2Capecitabine 2tipifarnib 1olutasidenib 1entinostat 1Trastuzumab 1Thalidomide 1Specimen Handling 1Quality of Life 1Patient Reported Outcome Measures 1Oxaliplatin 1Observation 1Molecular Diagnostic Techniques 1Magnetic Resonance Spectroscopy 1Leucovorin 1Irinotecan 1Ipilimumab 1Immunotherapy 1Gemcitabine 1Floxuridine 1Fentanyl 1Erlotinib Hydrochloride 1Epirubicin 1Drug Therapy 1Docetaxel 1Cetuximab 1Carboplatin 1CTLA-4 Antigen 1Biological Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Bile Duct Neoplasms × Nivolumab × CNS × Clear all
NCT02834013 2026-06-03

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

National Cancer Institute (NCI)

Phase 2 Active not recruiting
798 enrolled
CNSDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckSarcoma

Nasopharyngeal Carcinoma, Bile Duct Neoplasms, Carcinoma, Basal Cell, Adenocarcinoma, Bronchiolo-Alveolar, Adenocarcinoma, Mucinous, Carcinoma, Transitional Cell, Carcinosarcoma, Chordoma, Carcinoma, Adenoid Cystic, Fibroma, Gallbladder Neoplasms, Hemangiosarcoma, Mouth Neoplasms, Paget Disease, Extramammary, Paraganglioma, Paranasal Sinus Neoplasms, Parathyroid Neoplasms, Pheochromocytoma, Pseudomyxoma Peritonei, Somatostatinoma, Thyroid Neoplasms, Vulvar Neoplasms, Desmoid Tumors, Seminoma, Carcinoma, Acinar Cell, Adrenocortical Carcinoma, Carcinoma, Endometrioid, Cholangiocarcinoma, Cystadenocarcinoma, Mucinous, Cystadenocarcinoma, Serous, Carcinoma, Giant Cell, Neurofibrosarcoma, Gestational Trophoblastic Disease, Rare Diseases, Gastrointestinal Stromal Tumors, Perivascular Epithelioid Cell Neoplasms

NCT03684811 2023-11-18

A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation

Novo Nordisk A/S

Phase 1/2 Completed
93 enrolled 24 charts
CNSGastrointestinal

Bile Duct Neoplasms, Glioblastoma, Carcinoma, Hepatocellular, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡